{"preliminary_commentary":{"by_channel":{"x_thread":4},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":false},"commentary_summary":null,"drugs_tested":[["acalabrutinib"]],"indication":"previously untreated mantle cell lymphoma","name":"NCT02972840","nct_id":"NCT02972840","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct02972840. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Acalabrutinib administered twice per day (BID) orally (PO) plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.","label":"Acalabrutinib in combination with bendamustine and rituximab","type":"EXPERIMENTAL"},{"description":"Matching placebo administered BID PO plus bendamustine on Days 1 and 2 and rituximab on Day 1; cycles are repeated every 28 days.","label":"Placebo in combination with bendamustine and rituximab","type":"PLACEBO_COMPARATOR"}],"collaborators":["AstraZeneca"],"completion_date":{"date":"2027-02-15","type":"ESTIMATED"},"conditions":["Lymphoma, Mantle Cell"],"enrollment":{"count":635,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Acalabrutinib","otherNames":["ACP-196","Calquence"],"type":"DRUG"},{"name":"Bendamustine","otherNames":["Treanda","Bendeka"],"type":"DRUG"},{"name":"Rituximab","otherNames":["Rituxan","Rituxan Hycela"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-10-08","lead_sponsor":"Acerta Pharma BV","official_title":"A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination With Acalabrutinib (ACP-196) in Subjects With Previously Untreated Mantle Cell Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-02-15","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free survival per the Lugano Classification for NHL in Arm 1 compared to Arm 2","timeFrame":"Up to 6 years"}],"references":[{"citation":"Wang M, Salek D, Belada D, Song Y, Jurczak W, Kahl BS, Paludo J, Chu MP, Kryachok I, Fogliatto L, Cheah CY, Morawska M, Sancho JM, Li Y, Patti C, Forsyth C, Zhang J, Lesley R, Ramadan S, Rule S, Dreyling M; ECHO investigators; ECHO Investigators. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. 2025 Jul 10;43(20):2276-2284. doi: 10.1200/JCO-25-00690. Epub 2025 May 1.","pmid":"40311141","type":"DERIVED"}],"start_date":{"date":"2017-04-05","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","url":"https://clinicaltrials.gov/study/NCT02972840"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct02972840"}